Management of Staphylococcus aureus Bacteremia

Initial Empiric Therapy

• The Infectious Diseases Society of America recommends initial empiric therapy with vancomycin or daptomycin for gram-positive cocci in clusters bacteremia, likely Staphylococcus aureus, with prompt de-escalation to a β-lactam if methicillin-susceptible S. aureus (MSSA) is confirmed 1, 2, 3, 4
• Daptomycin IV 6 mg/kg once daily is a first-line option, with some experts recommending higher doses of 8-10 mg/kg once daily for better outcomes 1, 2, 3
• Vancomycin (15-20 mg/kg IV q8-12h, adjusted for renal function) is recommended as first-line empiric therapy for patients with Gram-positive bacteremia, according to the European Society for Medical Oncology and the Infectious Diseases Society of America 4, 5

Duration of Therapy

• Minimum 2 weeks of therapy is recommended for uncomplicated bacteremia 1, 3, 4
• 4-6 weeks of therapy is recommended for complicated bacteremia, which includes persistent bacteremia, metastatic infections, endocarditis, and implanted devices/prosthetic material 1, 3
• Recommended treatment durations for various conditions are as follows:

3, 6, 7, 8

Diagnosis and Management

• Follow-up blood cultures should be obtained at 2-4 days after initial positive cultures to document clearance of bacteremia 1, 3
• Echocardiography, preferably transesophageal echocardiography (TEE), should be performed in all patients with S. aureus bacteremia to rule out endocarditis 1, 3
• Identification and elimination of the source of infection, including removal of infected intravascular catheters, drainage of abscesses, and debridement of infected tissue, is critical for successful treatment 1, 3
• Catheter removal is strongly recommended for S. aureus catheter-related infections, as failure or delay in removing catheters increases the risk for hematogenous complications 6
• Consider removal of implanted devices, particularly cardiovascular implantable electronic devices, due to the high rate of device seeding (34% in patients with indwelling devices) 2
• Surgical evaluation for drainage of contiguous sites of infection or abscess is strongly recommended whenever possible (A-II) 3

Antibiotic Therapy

• Addition of gentamicin to vancomycin is NOT recommended for bacteremia or native valve endocarditis 1, 3
• Addition of rifampin to vancomycin is NOT recommended for bacteremia or native valve endocarditis 1, 3
• Suboptimal vancomycin dosing can lead to treatment failure and resistance development, emphasizing the importance of adequate dosing 2
• Alternative antibiotics for MRSA include linezolid, daptomycin, and ceftaroline, with telavancin and quinupristin-dalfopristin considered for specific cases 9, 3
• Clindamycin provides excellent coverage against gram-positive anaerobic cocci, including Peptostreptococcus species, and is recommended by the Infectious Diseases Society of America for MRSA wound infections when local resistance rates are low (<10%) 10, 1
• Vancomycin has limitations, including increasing MICs affecting efficacy, poor tissue penetration, and nephrotoxicity concerns, and should be used with caution 9

Prevention and Follow-up

• Emphasizing hygiene measures, such as covering draining wounds, regular handwashing, avoiding sharing personal items, and cleaning high-touch surfaces, is crucial for preventing recurrent infections, with a strength of evidence considered high 1, 3
• Tetanus prophylaxis should be considered if indicated, with a strength of evidence considered high 11
• A comprehensive decolonization protocol should include chlorhexidine body washes daily for 5-14 days, laundering clothing, towels, and bedding in hot water, and avoiding sharing personal items (razors, towels) 1
• Hospitalization should be considered if there is evidence of deeper or necrotic infection, systemic symptoms, hemodynamic instability, immunocompromised status, or poor adherence to outpatient therapy, as recommended by the Infectious Diseases Society of America 11
• Follow-up blood cultures should be performed 2-4 days after initial positive cultures to document clearance of bacteremia, as recommended by the Infectious Diseases Society of America 3
• A minimum of 12 months follow-up after cessation of therapy for implant-related infections is recommended 12
• Patients should be monitored for Clostridium difficile colitis, which can occur with either agent 7